regulation

GLP-1 Eye Warning Spans Full Class in US, Not in UK

The US now requires a vision loss warning on every GLP-1 medicine, while the UK warning from February 2026 still covers semaglutide and no other GLP-1 drug

Regulatory documents representing a medicines safety labelling decision

The US Food and Drug Administration told the manufacturers of every GLP-1 receptor agonist medicine on 9 November 2026 to add a warning about a rare eye condition to the Warnings and Precautions section of their labelling. The condition, non-arteritic anterior ischemic optic neuropathy or NAION, can cause sudden, painless loss of vision in one eye, and the FDA says that loss can be permanent. The requirement covers the whole class, whether a medicine is licensed for type 2 diabetes or for weight management, so it reaches tirzepatide, sold as Mounjaro, as well as semaglutide. The Medicines and Healthcare products Regulatory Agency issued a Drug Safety Update on 5 February 2026 covering semaglutide alone, the active ingredient in Ozempic, Wegovy and Rybelsus. The MHRA wrote then that other GLP-1 agonists were not included in the European review behind its decision, and that it was reviewing any evidence for an association with the rest of the class. It has published nothing further on NAION since.

What the FDA's own figures show

The FDA pooled 126 trials covering 134,253 patients and 288,879 patient-years of exposure. It identified 15 probable NAION events, 10 among people taking a GLP-1 receptor agonist and 5 among those on a placebo, an incidence of 6.4 events per 100,000 patient-years against 3.8 in comparator groups. A separate retrospective cohort study in the agency's Sentinel data found no statistically significant increase in risk against SGLT-2 inhibitors, with a hazard ratio of 1.19 and a confidence interval of 0.91 to 1.54, and an increased risk against DPP-4 inhibitors, at 1.43 and 1.02 to 2.01. The FDA says its review of animal data identified no mechanism for how these medicines could raise the risk.

What this means in practice

The MHRA's February update applies across the UK, so Great Britain and Northern Ireland are covered alike, and the divergence sits between the UK and the US. The agency put the frequency at up to 1 in 10,000 people taking semaglutide, and said a European review suggested roughly one additional person affected per 10,000 treated each year among adults with type 2 diabetes. It recorded three UK Yellow Card reports suggestive of NAION between semaglutide's first authorisation in 2018 and 1 August 2025, against an estimated 10.2 million packs dispensed over five years. The MHRA also noted that privately prescribed semaglutide may not appear in a patient's medical history, and it advises anyone whose sight suddenly worsens during treatment to attend eye casualty or A&E urgently. Sharon Heng, a consultant ophthalmic surgeon at Moorfields Eye Hospital, told Optometry Today that some patients had stopped taking GLP-1 medicines out of concern for their eyesight, adding: “We would ask that patients speak to their prescribers or GP prior to stopping the medication.”

Why this article carries no offer

This is a prescription medicine safety story, so it carries no product link and no membership offer. Perqen does not sell or arrange prescription medicines. The full Perqen catalogue lists what we do stock.

This article reports published news and research and is for information only. Food supplements are not a substitute for a varied diet or medical care, and no product mentioned is intended to diagnose, treat, cure or prevent any disease. Speak to your GP or pharmacist before changing what you take, especially if you are pregnant, breastfeeding, or taking prescribed medicines.

Sources